# A Study of Intravenous EEDVsMit in Children With Recurrent / Refractory Solid or CNS Tumours Expressing EGFR

> **NCT02687386** · PHASE1 · TERMINATED · sponsor: **Dr David Ziegler** · enrollment: 9 (actual)

## Conditions studied

- Solid Tumours
- CNS Tumours

## Interventions

- **DRUG:** Mitoxantrone packaged EDV (EnGeneIC Delivery Vehicle)

## Key facts

- **NCT ID:** NCT02687386
- **Lead sponsor:** Dr David Ziegler
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-02-08
- **Primary completion:** 2021-12-29
- **Final completion:** 2021-12-29
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Study medication no longer in production
- **Last updated:** 2022-02-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02687386

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02687386, "A Study of Intravenous EEDVsMit in Children With Recurrent / Refractory Solid or CNS Tumours Expressing EGFR". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02687386. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*